Translational Research on Epidermal Growth Factor Receptor Gene Mutations in Targeted Therapy for Patients with Advanced Non-Small Cell Lung Cancer

Translational Research on Epidermal Growth Factor Receptor Gene Mutations in Targeted Therapy for Patients with Advanced Non-Small Cell Lung Cancer

Abstract Objective: To explore the significance of epidermal growth factor receptor (EGFR) gene mutations in targeted therapy for patients with advanced non-small cell lung cancer (NSCLC). Methods: One hundred and seventeen patients with advanced NSCLC admitted in Maternal and Child Health Care Cent...

Full description

Bibliographic Details
Main Authors:	Xiao-yan WANG, Er-xi ZHOU
Format:	Article
Language:	English
Published:	Third Party Medicine International Publishing Group Co. Limited 2015-12-01
Series:	Journal of International Translational Medicine
Subjects:	EGFR Mutations Targeted therapy Non-small cell lung cancer Translational medicine
Online Access:	http://www.jitm.hk/EN/abstract/abstract175.shtml

Similar Items

Characteristics of Epidermal Growth Factor Receptor with Rare Mutations in Non-small Cell Lung Cancer and the Effect of EGFR Tyrosine Kinase Inhibitors on Them
by: Yunshu SHI, et al.
Published: (2019-05-01)

Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor  Receptor Mutations in Non-small Cell Lung Cancer
by: Xue YANG, et al.
Published: (2015-08-01)

Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data
by: S.E.D.C. Jorge, et al.
Published: (2014-11-01)

Recent Management of Patients with Advanced Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer: Role of Afatinib and Lesson Learned for Developing Countries
by: Zulkifli Amin, et al.
Published: (2017-04-01)

Case Report: Long Progression-Free Survival of Immunotherapy for Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutation
by: Jianfeng Peng, et al.
Published: (2021-09-01)

Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis
by: Kun-Ming Rau, et al.
Published: (2016-04-01)

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients
by: Carlos E. Bacchi, et al.
Published: (2012-01-01)

EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry
by: Zohra Mraihi, et al.
Published: (2018-08-01)

Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet Digital PCR
by: Masaru Watanabe, et al.
Published: (2017-07-01)

Clinical Features of EGFR Double Mutation in Non-small Cell Lung Cancer
by: Mengyao WANG, et al.
Published: (2018-08-01)

Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
by: Wu JY, et al.
Published: (2016-10-01)

Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study
by: Wenjing Yang, et al.
Published: (2017-11-01)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
by: Wu Z, et al.
Published: (2019-10-01)

Comparison of the analytical performance between the Oncomine Dx Target Test and a conventional single gene test for epidermal growth factor receptor mutation in non‐small cell lung cancer
by: Tadashi Sakaguchi, et al.
Published: (2021-02-01)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
by: Kejun Liu, et al.
Published: (2020-01-01)

Pooled Analysis of the Trials of Erlotinib Monotherapy for Epidermal Growth Factor Receptor (EGFR)-mutant Advanced Non-small Cell Lung Cancer
by: Li MA, et al.
Published: (2009-12-01)

Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors
by: Clémentine Bouchez, et al.
Published: (2020-12-01)

Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation
by: Yosuke Miyashita, et al.
Published: (2021-02-01)

Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis
by: Fei Chen, et al.
Published: (2020-06-01)

Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation
by: Ayako Morita, et al.
Published: (2021-04-01)

Histologic Grade Is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma
by: Michelle Levy, et al.
Published: (2017-12-01)

Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study
by: Mariko Kogo, et al.
Published: (2020-02-01)

Epidermal Growth Factor Receptor Mutations Carried in Extracellular Vesicle-Derived Cargo Mirror Disease Status in Metastatic Non-small Cell Lung Cancer
by: Emma Purcell, et al.
Published: (2021-10-01)

Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer
by: Mercedes Delgado-García, et al.
Published: (2020-04-01)

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
by: Taiji Kuwata, et al.
Published: (2016-10-01)

The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations
by: Yongdong Feng, et al.
Published: (2021-05-01)

Selective Targeting of the L858R Mutation (EGFR) in Non-Small Cell Lung Cancer: A Mechanism for Advancing Targeted Chemotherapy
by: Rohan Arora, et al.
Published: (2017-05-01)

Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review
by: Yoko Yamamoto, et al.
Published: (2017-11-01)

Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patients
by: Obradovic Jasmina, et al.
Published: (2012-12-01)

Clinical Analysis of Icotinib on Beneficiary of  Advanced Non-small Cell Lung Cancer with EGFR Common Mutation
by: Xiaowen JIANG, et al.
Published: (2016-04-01)

AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES
by: E. V. Karabina, et al.
Published: (2017-11-01)

Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A
by: Cheol‐Kyu Park, et al.
Published: (2021-02-01)

Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
by: Peng D, et al.
Published: (2021-02-01)

Post‐progression survival is highly linked to overall survival in patients with non‐small‐cell lung cancer harboring sensitive EGFR mutations treated with first‐line epidermal growth factor receptor‐tyrosine kinase inhibitors
by: Hisao Imai, et al.
Published: (2019-12-01)

Real‐world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non‐small cell lung cancer
by: Shirley Xue Jiang, et al.
Published: (2019-12-01)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
by: Anna Maria Rachiglio, et al.
Published: (2019-03-01)

Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
by: Shuping XUE, et al.
Published: (2015-10-01)

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer
by: Tadaaki Yamada, et al.
Published: (2019-04-01)

The comparative pharmacoeconomic analysis of tyrosine kinase inhibitor Iressa® (gefitinib) with TKI Giotrif® (afatinib) as first-line therapy for patients with advanced non-small cell lung cancer associated with mutations in the epidermal growth factor receptor
by: V V Ryazhenov
Published: (2017-01-01)

Genetic heterogeneity of EGFR and KRAS mutations in primary tumor tissue from non-small cell lung cancer patients
by: Mattsson, Johanna
Published: (2011)